期刊文献+

四氧嘧啶制作新西兰大白兔糖尿病心肌病模型方法的研究 被引量:1

Research of alloxan-induced diabetic cardiomyopathy model in rabbits
下载PDF
导出
摘要 目的探讨四氧嘧啶(ALX)制作新西兰大白兔糖尿病心肌病模型的方法。方法选取健康新西兰大白兔30只,随机分为实验组(20只)和对照组(10只)。实验组经耳缘静脉注射5%ALX溶液,24h后再次注射,注射剂量均为80mg/kg;对照组注射等量的0.9%氯化钠注射液。分别监测两组兔注射后72h及2、4周的空腹血糖,并在饲养4周后分别左心室心肌行HE染色,观察心肌细胞病理变化。结果实验组14d内累计死亡8只.1只血糖恢复正常,成模率55%(11/20);对照组无死亡。实验组成模兔注药后空腹血糖均较对照组兔明显增高,差异均有统计学意义(均P〈0.05)。4周后实验组兔心肌细胞排列不整齐,心肌细胞肿胀。间质纤维组织增多,心肌细胞浆空泡变性,炎细胞浸润。结论分次小剂量注射ALX制作糖尿病兔模型成功率较高,可建立稳定的糖尿病兔心肌病模型。 Objective To establish a diabetic cardiomyopathy rabbit model by injection of alloxan(ALX). Methods Thirty healthy New Zealand white rabbits weighing 2.0-2.5kg were randomly divided into experimental group (n=20) and control group (n=10). All rabbits were fasted for 12 hours,animals in experimental group were injected with 80mg/kg newly prepared 5% ALX, 24h later, injected the same dose again; animals in the control group were injected with same volume of normal saline. The fasting blood glucose levels were measured at 72h, 2w and 4w, respectively. The rabbits were sacrificed 4 weeks later, the pathological changes of left ventricular myocardium were observed under microscope. Results Eight rabbits in experiment group died in 14d and the fasting blood glucose of one rabbit returned to normal; the success rate of diabetic rabbit model was 55%(11/20). There was no death in control group. Fasting blood glucose of experimental group was rising significantly compared with control group (P〈0.05); the pathology showed vacuolar degeneration and necrosis in myocardiocytes and local inflammatory cells infiltration. Conclusion Multiple, low dose administration of ALX is effective to establish diabetic cardiomyopathy model in rabbits.
出处 《浙江医学》 CAS 2012年第15期1273-1275,共3页 Zhejiang Medical Journal
基金 浙江省自然科学基金资助项目(Y2110934)
关键词 新西兰大白兔 四氧嘧啶 糖尿病心肌病 病理 Rabbit Atloxan Diabetic cardiomyopathy Pathology
  • 相关文献

参考文献7

  • 1Wentao S,Chunling L,Sihai Z,et al.Optimized alloxan-induced diabetic rabbit model[J].lnt J Ophthalmol,2010,10(10):1848- 185O.
  • 2Jolanda M,van Golde J M,Ruiter M S,et al.lmpaired collateral re- cruitment and outward remdeling in experimental diabetes[J].Di- abetes,2008,57(10):2818-2823.
  • 3Lenzen S.The mechanisms of alloxan and streptozotocin in- Juced diabetes[J].Diabetologia,2008,51 (2):216-226.
  • 4艾静,王宁,杜杰,杨梅,刘萍,杜智敏,杨宝峰.Wistar大鼠2型糖尿病动物模型的建立[J].中国药理学通报,2004,20(11):1309-1312. 被引量:33
  • 5徐淑云,卞如濂,陈修.药理实验方法学[M].3版.北京:人民卫生出版社,2002:1346-1347
  • 6查彦红,谷卫.糖尿病动物模型的研究进展[J].浙江医学,2007,29(12):1342-1345. 被引量:12
  • 7Lenzen S.The mechanisma of alloxan-and streptozotoein-in- duced diabetes[J].Diabetologia,2008,51:216-226.

二级参考文献29

  • 1孙敬方.动物实验方法学[M].北京:人民卫生出版社,2002.473-474,493.
  • 2Coleman DL. Obese and diabetes:Mutant genes causing diabetes-obesity syndromes in mice[J]. Diabetologia, 1998,14(3):141-8.
  • 3林志彬. 正糖钳技术[M].见:徐淑云,卞如濂,陈修主编.药理实验方法学, 第3版,北京,人民卫生出版社,2002:1522-3.
  • 4Severino C, Brizzi P, Solinas A et al. Low-dose dexamethasone in the rat:Model to study insulin resistance[J]. Am J Physiol Endocrinol Metab, 2002,283(2):367-73.
  • 5Penicaud L, Berthault MFM, Morin J et al. Pilmenidine normalizes fructose-induced insulin resistance and hypertension in rats[J].J Hypertens Suppl, 1998,16(3):S45-9.
  • 6Lombardo YB, Drago S, Chicco A et al. Long-term administration of a sucrose-rich diet to mormal rats: relationship between metabolic and hormonal profiles and morphological changes in the endocrine pancreas[J].Metablism, 1996,45(12):1572-32.
  • 7Baptista T, Alvares L, Lacruz A et al. Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs[J]. Prog Neuropsychopharmacol Biol Psychiatry, 1999,23(2):277-87.
  • 8Abe H, Yamada N. Animal models for hyperinsulinemia and insulin resistance[J].Ann N Y Acard Sci, 2000,902:134-9.
  • 9Anuradha CV, Balakrishnan SD. Taurine attenuates hypertension and improves insulin sensitivity in the fructose-fed rat, an animal model of insulin resistance[J].Can J Pharmacol, 1999,77(10):749-54.
  • 10Mathews C E. Utility of murine models for the study of spontaneous autoimmune type 1 diabetes[J]. Pediatr Diabetes, 2005, 6(3):165- 177.

共引文献144

同被引文献17

  • 1Maahs D M, Dabelea D, D'Agostino R B Jr, et al. Glucose control predicts 2-year change in lipid profile in youth with type 1 dia- betes[J]. J Pediatr,2013,162(1):101-107.
  • 2Maahs D M, Wadwa R P, Bishop F, et al. Dyslipidemia in youth with diabetes: to treat or not to treat[J].? J Pediatr, 2008, 153(4):458- 465.
  • 3Renard C B, Kramer F, Johansson F, et al. Diabetes and dia- betes-associated lipid abnormalities have distinct effects on initi- ation and progression of atherosclerotic lesions[J]. J Clin Invest, 2004,114(5):659-668.
  • 4Johansson F, Kramer F, Barnhart S, et al. Type 1 diabetes pro- motes disruption of advanced atherosclerotic lesions in LDL-C receptor-deficient mice[J]. Proc Natl Acad Sci U S A, 2008, 105 (6):2082-2087.
  • 5The Diabetes Control and Complications Trial Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications of insulin-depen-dent diabetes mellitus[J]. N Engl J Med, 1993, 329(14):977-986.
  • 6The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascu- lar events and risk factors in the diabetes control and complica- tions trial[J]. Am J Cardiol,1995,75:894-903.
  • 7Maahs D M, Ogden L G, Dabelea D, et al. Association of gly- caemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication[J]. Diabetologia, 2010, 53(12): 2518- 2525.
  • 8de Boer I H, Kestenbaum B, Rue T C, et al. Insulin therapy, hyper- glycemia, and hypertension in type 1 diabetes mellitus[J]. Arch Intern Med, 2008,168:1867-1873.
  • 9Nathan D M, Cleary P A, Backlund J Y, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 dia- betes[J]. N Engl J Med,2005,353:2643-2653.
  • 10Teramoto T, Shirai K, Daida H,et al. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study[J]. Cardiovasc Diabetol, 2012, 11:29-39.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部